Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
NTLA · Why this verdict
Why Intellia Therapeutics (NTLA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score3.8/10
ConfidenceHIGH
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Intellia Therapeutics is a cash-burning gene editing company with two high-concentration pipeline programs — lonvo-z for HAE and nex-z for ATTR amyloidosis — where short interest of 44% reflects deep skepticism, but a perfect 4-quarter earnings beat streak and 78% analyst upside indicate institutional believers see a path to significant value creation.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Intellia's investment thesis is concentrated in two programs — lonvo-z targeting hereditary angioedema and nex-z targeting ATTR amyloidosis — creating a binary risk profile where clinical outcomes in these programs will dominate stock performance. Bear case | At least one of the two key programs reports a positive clinical or regulatory milestone within 12 months that validates the gene editing approach. | →Stable |
| CounterConcentrated biotech pipelines can create asymmetric reward profiles when programs succeed; both target diseases with high unmet need and established market precedents for premium pricing. | ||
Short interest stands at 44% of the float, the highest level of skepticism among peers, indicating that a very large proportion of active market participants are positioned for the stock to decline or program failures to materialize. Key risks | Short interest falls below 30% within 12 months as positive clinical news or partnership announcements reduce the bearish conviction in the market. | →Stable |
| CounterExtremely high short interest of 44% creates a potential for a substantial short squeeze if positive news surprises; the stock has already demonstrated a 2.7x average volume surge on up moves suggesting latent buying interest. | ||
Intellia burns cash at 356% of revenue and carries a quality score of 1.8, well below the minimum acceptable floor of 4.0, with a Piotroski F-Score of only 3/9, reflecting the pre-revenue nature of the business. Quality breakdown | Cash burn as a percentage of revenue declines below 250% within 12 months as programs advance to later stages with milestone or collaboration payments. | →Stable |
| CounterThe current ratio scores a high 6.9 indicating the balance sheet is sufficiently capitalized near-term; pre-revenue biotechs with strong pipelines are expected to burn cash at this stage. | ||
Despite being pre-revenue, Intellia has beaten analyst EPS estimates in all 4 of the last 4 quarters with an average positive surprise of 8.5%, and analysts maintain a consensus price target implying 78% upside, reflecting confidence in the platform's progression. Catalyst breakdown | Beat rate remains at 4 out of 4 quarters with positive EPS surprises continuing, and at least 1 new analyst initiates coverage with a price target above $22. | →Stable |
| CounterBeating loss estimates at a pre-revenue biotech means burning less cash than feared, not demonstrating profitability; analyst upside targets are purely option-value based and can disappear rapidly on trial failure. | ||
Intellia's investment thesis is concentrated in two programs — lonvo-z targeting hereditary angioedema and nex-z targeting ATTR amyloidosis — creating a binary risk profile where clinical outcomes in these programs will dominate stock performance.
→StableBear case
- Expectation
- At least one of the two key programs reports a positive clinical or regulatory milestone within 12 months that validates the gene editing approach.
CounterConcentrated biotech pipelines can create asymmetric reward profiles when programs succeed; both target diseases with high unmet need and established market precedents for premium pricing.
Short interest stands at 44% of the float, the highest level of skepticism among peers, indicating that a very large proportion of active market participants are positioned for the stock to decline or program failures to materialize.
→StableKey risks
- Expectation
- Short interest falls below 30% within 12 months as positive clinical news or partnership announcements reduce the bearish conviction in the market.
CounterExtremely high short interest of 44% creates a potential for a substantial short squeeze if positive news surprises; the stock has already demonstrated a 2.7x average volume surge on up moves suggesting latent buying interest.
Intellia burns cash at 356% of revenue and carries a quality score of 1.8, well below the minimum acceptable floor of 4.0, with a Piotroski F-Score of only 3/9, reflecting the pre-revenue nature of the business.
→StableQuality breakdown
- Expectation
- Cash burn as a percentage of revenue declines below 250% within 12 months as programs advance to later stages with milestone or collaboration payments.
CounterThe current ratio scores a high 6.9 indicating the balance sheet is sufficiently capitalized near-term; pre-revenue biotechs with strong pipelines are expected to burn cash at this stage.
Despite being pre-revenue, Intellia has beaten analyst EPS estimates in all 4 of the last 4 quarters with an average positive surprise of 8.5%, and analysts maintain a consensus price target implying 78% upside, reflecting confidence in the platform's progression.
→StableCatalyst breakdown
- Expectation
- Beat rate remains at 4 out of 4 quarters with positive EPS surprises continuing, and at least 1 new analyst initiates coverage with a price target above $22.
CounterBeating loss estimates at a pre-revenue biotech means burning less cash than feared, not demonstrating profitability; analyst upside targets are purely option-value based and can disappear rapidly on trial failure.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.9 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -356% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
0.1/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.1 |
- ▸Declining revenue: -10%
Momentum
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 9.8 |
| erm sentiment | 4.4 |
- ▸Analyst upside: 67%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
1.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.5 |
| quality rank | 1.9 |
| growth rank | 2.3 |
Technical
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.3 |
| support resistance | 1.6 |
| 52w position | 1.3 |
Risk (lower is worse)
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 3.8 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 4.0 |
| debt equity | 9.5 |
- ▸High short interest justified: 44%
- ▸High IV: 103%
- ▸Above max pain $1
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 6.6 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.9>=5.5
- ASYMMETRY:3.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
3.35
Upside
+50.3%
Downside
15.0%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 57, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.81>1.3, MCap $2.2B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.4 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 7.4, Momentum at 6.9, and Catalyst at 6.7; the weakest are Growth at 0.1, Technical at 1.4, and Peer rank at 1.4. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 3.35 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Intellia's investment thesis is concentrated in two programs — lonvo-z targeting hereditary angioedema and nex-z targeting ATTR amyloidosis — creating a binary risk profile where clinical outcomes in these programs will dominate stock performance.
Trip ifA clinical hold or negative Phase 2 readout is reported for either lonvo-z or nex-z, causing the stock to fall below $10.
- P2Short interest stands at 44% of the float, the highest level of skepticism among peers, indicating that a very large proportion of active market participants are positioned for the stock to decline or program failures to materialize.
Trip ifShort interest rises above 50% or days-to-cover increases above 10.
- P3Intellia burns cash at 356% of revenue and carries a quality score of 1.8, well below the minimum acceptable floor of 4.0, with a Piotroski F-Score of only 3/9, reflecting the pre-revenue nature of the business.
Trip ifCash burn rate increases above 400% of revenue for 2 consecutive quarters without a corresponding partnership announcement.
- P4Despite being pre-revenue, Intellia has beaten analyst EPS estimates in all 4 of the last 4 quarters with an average positive surprise of 8.5%, and analysts maintain a consensus price target implying 78% upside, reflecting confidence in the platform's progression.
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters or analyst consensus target declines below $18.